Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Avila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores
Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the 99m Tc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid (99m Tc-HYNIC-D-Alanine-BoroPro)(99m Tc-HYNIC-iFAP) structure for tumor microenvironment SPECT imaging. This research aimed to synthesize 68 Ga-[2,2',2″,2‴-(2-(4-(2-(5-(((S)-1-((S)-2-boronopyrrolidin-1-yl)-1-oxopropan-2-yl)carbamoyl)pyridin-2-yl)hydrazine-1-carbothioamido)benzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid] (68 Ga-DOTA-D-Alanine-BoroPro)(68 Ga-iFAP) as a novel radiotracer for PET imaging and evaluate its usefulness for FAP expression in malignant and non-malignant tissues...
April 12, 2024: Pharmaceutics